

REPhRAME

REcurrent urinary tract infection:
Efficacy and safety of PHage
theRapy and Microbiota transfEr.



FACT SHEET



REPhRAME

ACRONYM

REPhRAME

FULL TITLE

REcurrent urinary tract infection:
Efficacy and safety of PHage theRapy and Microbiota transfEr

PROGRAMME

Horizon Europe

CONTRACT NUMBER

101287159

ABSTRACT

Recurrent urinary tract infections (rUTIs) impose a substantial clinical and socio-economic burden on patients and healthcare systems, particularly affecting women. Treatment still relies heavily on antibiotics, which contributes to antimicrobial resistance (AMR) and may reduce or even hinder long-term therapeutic effectiveness.

The REPhRAME project addresses this urgent unmet need by investigating innovative, non-antibiotic strategies. The project evaluates a bacteriophage-based investigational medicinal product to treat acute infections and fecal microbiota transplantation (FMT-IMP) to prevent recurrence by restoring a healthier microbiome.

Building on a seamless Phase Ib/IIa randomised controlled trial, REPhRAME will assess optimal routes of administration, clinical efficacy, reduction in antibiotic use and prevention of recurrent infections. Multi-omics analyses, biomarker discovery, and health economic modelling complement the clinical trial, while patient engagement, ethical oversight, and regulatory alignment ensure societal relevance and translational impact.

By combining precision medicine, novel biologics manufacturing, and robust clinical evidence, REPhRAME aims to pioneer sustainable alternatives to antibiotics in patients with rUTIs, improve patients' quality of life and support goals of the European Union in AMR mitigation and healthcare innovation.

DURATION

60 months (01 June 2026 - 31 May 2031)

PROJECT FUNDING

15,199,939.18 EUR

COORDINATOR

Prof Maria Vehreschild

Johann Wolfgang Goethe-Universität Frankfurt am Main (Germany)

Email: vehreschild@med.uni-frankfurt.de

PARTNERS

- Klinikum der Universität zu Köln (Germany)
- Universitätsklinik Balgrist, Universität Zürich (Switzerland)
- Academisch Ziekenhuis Leiden (Netherlands)
- HUN-REN Szegedi Biológiai Kutatóközpont (Hungary)
- SIB Swiss Institute of Bioinformatics (Switzerland)
- Medizinische Hochschule Hannover (Germany)
- JAFRAL, biotehnoške raziskave in razvoj, d.o.o. (Slovenia)
- SNIPR Biome ApS (Denmark)
- Fraunhofer Gesellschaft, Fraunhofer ITMP (Germany)
- LINQ management GmbH (Germany)
- The University of Reading (United Kingdom)
- Universität Bern (Switzerland)
- University of Leicester (United Kingdom)
- Rīgas Stradiņa universitātē (Latvia)
- Deutsches Zentrum für Infektionsforschung (DZIF) e.V. (Germany)

PROJECT MANAGEMENT

Julia Büch

LINQ management GmbH (Germany)

Email: j.buech@linq-management.com

PROJECT WEBSITE

www.rephrame-project.eu



**Funded by
the European Union**

This project (N° 101287159) is funded by the European Union under the Horizon Europe research and innovation programme.